# US 2023/0054302 A1 · Composition Of Ferric Maltol For Oral Administration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054302 A1
- Document ID: US20230054302A1
- Status: Published application
- Kind: A1
- Application number: 17/874,838
- Filed: 2022-07-27
- Published: 2023-02-23
- Earliest claimed: 2021-08-06
- Assignees: Rk Pharma Inc.
- Applicants: Rk Pharma Inc.
- Inventors: Ravishanker Kovi; Prasad Vure; Raghu Rami Reddy Kasu; Thupalli Ajey Kumar Reddy; Yekkanti Vamshi; Jayraman Kannappan; Hardik Vyas
- Web page: https://patentgrep.com/patent/US20230054302A1

## CPC

- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 9/485: {Inorganic compounds}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to an improved composition of ferric maltol or ferric trimaltol for the treatment of iron deficiency, wherein the composition comprises the active ferric maltol or ferric trimaltol lower than 60% of the total composition weight. The compositions further can be a capsule or tablet or any other pharmaceutical solid dosage form, preferably a capsule in a hard gelatin in a size of 0 or 1, for oral administration.

## Claims

### Claim 1

A solid unit dosage form comprising: ferric maltol or ferric trimaltol as active ingredient and pharmaceutically acceptable excipients, wherein ferric maltol or ferric trimaltol formulation comprises lower than 60% of ferric maltol or ferric trimaltol of the combined weight with excipients.

### Claim 2 (depends on 1)

The formulation of claim 1, wherein the pharmaceutically acceptable excipients are selected from the group consisting of binders, diluents, surfactants or wetting agents, lubricants, antioxidants, glidants, chelating agents and a combination thereof.

### Claim 3 (depends on 1)

The formulation of claim 1, wherein ferric maltol is in the form of crystalline alpha form of ferric maltol and further composition comprises lower than 60% of ferric maltol or ferric trimaltol of the combined weight with excipients.

### Claim 4 (depends on 1)

The formulation of claim 1, wherein the solid dosage form can be tablets or capsules for oral administration.

### Claim 5 (depends on 1)

The formulation of claim 1, wherein the formulation of ferric maltol or ferric trimaltol is in the form of hard gelatin capsule having size 0 or 1.

### Claim 6 (depends on 1)

The formulation of claim 1, wherein the ferric maltol or ferric trimaltol formulation has a concentration equivalent to 25 to 35 mg of elemental iron.

### Claim 7 (depends on 1)

The formulation of claim 1, wherein at least 95% drug release dissolution profile is seen in pH 1.2 within 45 minutes.

### Claim 8 (depends on 1)

The formulation of claim 1, wherein the powder filled into the capsule is manufactured by dry compression or dry granulation.
